Clinical Trial Update: Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. [Phase 3]

View source ↗

Summary

Phase 3 imaging trial evaluating rhPSMA 7.3 (18F) for safety and diagnostic performance in newly diagnosed prostate cancer has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• rhPSMA 7.3 (18F)

Snippet

Sponsor: Blue Earth Diagnostics | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-02-26